Company intelligence / Profile preview
Selonterra
San Mateo, California, United Statesselonterra.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Selonterra has developed small molecule modulators targeting novel genetic mechanisms underlying neurodegenerative diseases. Their lead compounds restore gene expression dysfunctions associated with APOE4 in Alzheimer’s models and are advancing through lead optimization to IND-enabling studies. All pipeline programs are currently at the preclinical stage.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Michael J. Fox Foundation for Parkinson's Research (grant funding partner)
Beyond the preview
Go deeper on Selonterra.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selonterra.